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Joan M. Bathon,3 Naveed Sattar,4 and Janet S. Lee5
Objective. To evaluate associations between lipid
levels, inflammation, and rheumatoid arthritis (RA)
disease activity, at baseline and during treatment, with
the risk of major adverse cardiovascular events (MACE)
in tocilizumab-treated patients with RA.
Methods. In retrospective post hoc analyses, data
were pooled for 3,986 adult patients with moderate to
severe RA who received>1 dose of tocilizumab (4 mg/kg
or 8 mg/kg) intravenously every 4 weeks in randomized
controlled trials and extension studies. Cox propor-
tional hazards modeling was used to evaluate associa-
tions between baseline characteristics and posttreat-
ment changes in laboratory and disease characteristics
(week 24) and change in disease activity and laboratory
values from baseline to week 24 with the risk of future
MACE during extended followup.
Results. We identified 50 independently adjudi-
cated cases of MACE during 14,683 patient-years of
followup (0.34 MACE cases/100 patient-years). At base-
line, age, a history of cardiac disorders, the Disease
Activity Score in 28 joints (DAS28), and the total
cholesterol:high-density lipoprotein cholesterol ratio
were independently associated with MACE in multivari-
able models (P < 0.05 for all). During treatment, a
higher DAS28 and higher swollen and tender joint
counts at week 24 were associated with future MACE. In
separate models, greater reductions in the DAS28 and
joint counts from baseline to week 24 were inversely
associated with future MACE; changes in lipid para-
meters were not statistically significantly associated
with the risk of MACE.
Conclusion. In this population of patients treated
with tocilizumab, an association was observed between
the baseline total cholesterol:high-density lipoprotein
cholesterol ratio and an increased risk of MACE. The
risk of MACE while receiving treatment, however, was
associated with control of disease activity but not lipid
changes. Larger studies are needed to confirm these
findings.
Patients with rheumatoid arthritis (RA) have
approximately double the risk of myocardial infarction
(MI) and stroke compared with that in the general
population (1,2). Several studies suggest that the in-
creased incidence of cardiovascular disease (CVD) in
RA is not completely explained by traditional CV risk
factors such as diabetes mellitus, hypertension, smoking,
and dyslipidemia (3–5). Indeed, the HLA–DRB1 shared
epitope, higher erythrocyte sedimentation rates (ESRs),
and RA comorbidities such as vasculitis and pulmonary
disease are associated with an increased risk of CVD-
related mortality (4,6). In a population-based incidence
cohort of RA patients with high ESRs, those with much
lower total cholesterol and low-density lipoprotein
Supported by F. Hoffmann-La Roche Ltd.
1Vijay U. Rao, MD, PhD (current address: Franciscan Pro-
vider Network, Indiana Heart Physicians, Indianapolis, Indiana),
Micki Klearman, MD, David Musselman, MD: Genentech, South
San Francisco, California; 2Andrey Pavlov, PhD: Everest Clinical
Research Services, Toronto, Ontario, Canada; 3Jon T. Giles, MD,
MPH, Joan M. Bathon, MD: Columbia University, New York, New
York; 4Naveed Sattar, MD, PhD: University of Glasgow, Glasgow,
UK; 5Janet S. Lee, PhD (current address: LifeTech Research, Edge-
water, Maryland): Roche, Nutley, New Jersey.
Dr. Rao was recipient of a Genentech Research Fellowship
with salary support during the study. Dr. Klearman owns stock or stock
options in Genentech. Dr. Giles has received consulting fees from
Genentech (less than $10,000). Dr. Sattar has received speaking fees
and consulting fees from Roche for serving on the Steering Committee
during the ENTRACTE (Arthritis and Cardiovascular Disease Risk
Factors) trial (less than $10,000).
Address correspondence to Micki Klearman, MD, Genen-
tech, 1 DNA Way, Mail Stop 304, South San Francisco, CA 94080.
E-mail: klearman.micki@gene.com.
Submitted for publication September 26, 2013; accepted in
revised form October 14, 2014.
372
(LDL) cholesterol levels were paradoxically at increased
risk of CVD (7). Thus, further exploration is needed to
determine the relative contributions of traditional CVD
risk factors, inflammation, and RA disease activity to the
risk of major adverse CV events (MACE) in the RA
patient population.
Multiple cohort studies suggest a relationship
between parameters of RA disease activity and an
increased risk of CV events (6,8,9). In fact, the occur-
rence of CV events appears to be lower in patients who
received nonbiologic disease-modifying antirheumatic
drugs (DMARDs) (10) and in those who responded to a
biologic DMARD compared with those who did not
(11). Furthermore, several studies have linked
interleukin-6 (IL-6), one of the primary drivers of RA-
related inflammation, with the development of coronary
heart disease in both patients with RA and the general
population (12–15).
Tocilizumab (TCZ) is a humanized monoclonal
antibody against the IL-6 receptor (IL-6R) that is ap-
proved for the treatment of patients with moderate to
severe RA in whom the response to a nonbiologic
DMARD was inadequate (16,17). Several randomized,
controlled, phase III clinical trials demonstrated the
efficacy and safety of TCZ in combination with nonbio-
logic DMARDs (18–21) or as monotherapy in patients
with RA (22–24). Treatment with TCZ results in eleva-
tions in mean lipid levels (total cholesterol, high-density
lipoprotein [HDL] cholesterol, LDL cholesterol, and
triglyceride). Although such elevations are similar to
those associated with treatment with other antiinflam-
matory agents (e.g., tumor necrosis factor  [TNF]
blockers), they are of greater magnitude (24,25). These
changes tend to occur within the first few weeks of treat-
ment and remain stable during long-term therapy (26).
The purpose of this analysis was to evaluate
whether baseline risk factors (demographic characteris-
tics, lipid levels, inflammation, and RA disease activity)
are associated with MACE in patients receiving TCZ
and, in particular, whether changes in the levels of lipids
and circulating inflammatory markers or changes in
RA-specific disease activity measures that occur with
TCZ treatment are associated with the risk of subse-
quent development of MACE.
PATIENTS AND METHODS
Data sources and patient populations. Using post hoc
retrospective analyses, we evaluated pooled data for adults
with moderate to severe RA who received at least 1 dose
of TCZ (4 mg/kg or 8 mg/kg) intravenously every 4 weeks,
in combination with methotrexate or other DMARDs or as
monotherapy, in registration trials (18–22) and in ongoing
extension studies up to the cutoff date of April 1, 2011 (Figure
1). All clinical and laboratory assessments for this analysis
were collected in accordance with the study protocol, at regular
intervals and at unscheduled visits as appropriate. All blood
samples (except those used for evaluation of the ESR) were
sent to a central laboratory (Covance Central Laboratory
Services) for processing. Assessment of the ESR was per-
formed at each study site using an ESR testing kit supplied by
Covance. Blood samples used for the assessment of lipid levels
were collected from each patient after an overnight fast.
MACE was defined as definite or probable nonfatal
MI, nonfatal stroke, or death caused by CVD. Records from
patients with serious adverse events in the Medical Dictionary
for Regulatory Activities (version 13.0) System Organ Classes
of cardiac, vascular, nervous system, and general disorders
were reviewed for potential major adverse CV–related events.
Cases were adjudicated in a blinded manner by an independent
cardiologist with experience serving on MACE adjudication
panels, who confirmed definite cases of MACE. The defini-
tions used are shown in Supplementary Table 1, available on
the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38920/abstract.
Statistical analysis. The demographic and baseline
characteristics of the patients (e.g., laboratory and RA disease
activity measures, medical history) were summarized descrip-
tively for patients with and those without MACE. Given that
not all patients were randomly assigned to TCZ at the start of
the studies, in this analysis, baseline was defined as the time
when the first dose of TCZ was administered.
Cox proportional hazards models were used to evalu-
ate associations between risk factors and time to development
of MACE. Associations were expressed in the form of hazard
ratios (HRs), and 95% confidence intervals (95% CIs) repre-
sented the uncertainty of the estimation. The HR was inter-
preted as a multiplier of the risk of MACE, corresponding to
a 1-unit increase in the predictor. Specific examples of inter-
pretation of the HR are shown in Figures 2–4. Cases of MACE
that began before the baseline visit were not counted in this
on-treatment analysis.
Patients were evaluated until withdrawal from the
study, completion of the study, or the initial occurrence of
MACE, whichever occurred first. In the event of multiple
occurrences of MACE, only the first was counted. Univariate
associations between demographic and baseline disease/
laboratory characteristics and time to future MACE were
examined by fitting separate models for each variable. Because
of the small number of events, limited multivariable modeling
was completed and focused on baseline/demographic charac-
teristics that might be important to evaluate in conjunction
with posttreatment changes in laboratory and disease charac-
teristics. Selection of baseline variables for the multivariable
Cox model was performed with the considerations described
here to ensure robustness and validity of the estimates. Highly
correlated variables, such as the swollen joint count (SJC),
tender joint count (TJC), and Disease Activity Score in 28
joints (DAS28) (27), were not entered together. The best score
method (28) was used to select between such variables. For-
ward, backward, and stepwise variable selection methods were
then used to verify the stability of selection.
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Changes in the predictors of MACE from baseline to
week 24 and time to future development of MACE were
evaluated after adjusting for age and baseline values to show
how treatment-initiated changes were associated with future
MACE. For these analyses, only patients with exposure after
the week 24 assessment were considered (i.e., patients who had
MACE before week 24 [n  8] or who had withdrawn or
completed the study by week 24 [n  220] were excluded).
Thus, 42 MACE cases that occurred after week 24 were
considered. Additionally, patients with missing data for a week
24 variable were excluded from the analysis of that variable.
Change from baseline was always calculated as the score at
week 24 minus the score at baseline; hence, negative-change
scores indicated decreases in the predictor value over time,
whereas positive-change scores indicated increases in the pre-
dictor value over time. The HRs in these analyses correspond
to a 1-unit increase in the predictor value from baseline (e.g.,
worsening joint counts or total cholesterol levels).
For all analyses of predictors, unadjusted P values less
than 0.05 were considered significant. Sensitivity analyses,
including 5 additional “probable” MACE cases, were con-
ducted to evaluate the stability of the results. Analyses using
laboratory and disease activity predictors observed at week 24
were conducted to further explore the associations between
the absolute values of these parameters and future MACE.
Such analyses are supportive of the baseline analysis in that
they also explore whether the absolute levels of laboratory and
disease activity parameters after TCZ exposure are predictive
of future MACE.
RESULTS
Exposure and disposition. For this analysis, the
total duration of TCZ exposure was 14,683 patient-
years. The mean SD duration of treatment was 3.68
1.79 years (median 4.54 years), and the maximum length
of TCZ exposure was 5.7 years. Independent adjudica-
tion of 102 potential cases of MACE in 3,986 patients
treated with TCZ, conducted in a blinded manner,
confirmed 50 cases, for a rate of 3.4/1,000 patient-years.
Characteristics of the patients with and those without
MACE at baseline are shown in Table 1. For the 50
patients with MACE, the median number of days from
administration of the first dose of TCZ to development
of MACE was 680 (range 29–1,792). MACE was ob-
served throughout the exposure period, with no obvious
time trends.
Figure 1. Data sources and patient disposition. OPTION  Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders study; TCZ 
tocilizumab; AMBITION  Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial
Hypertension; RADIATE  Research on Tocilizumab Determining Efficacy after Anti-TNF Failures; MACE  major adverse cardiovascular
event; TOWARD  Tocilizumab in Combination with Traditional DMARD Therapy; LITHE  The Tocilizumab Safety and the Prevention of
Structural Joint Damage study.
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Baseline predictors of MACE. Univariate analy-
sis demonstrated a statistically significantly increased
risk of MACE in patients with a history of cardiac
disorders, as reported by the investigators in these
clinical trials (HR 3.63, 95% CI 1.90–6.95, P  0.0001).
Other statistically significant baseline predictors of
MACE during TCZ treatment were older age, statin use
(although use of statins was low in patients with [16%]
and those without [9%] MACE) (Table 1), higher TJCs
and SJCs, a higher DAS28, a higher total cholesterol:
Table 1. Baseline characteristics of the patients with RA*
Characteristic MACE (n  50) No MACE (n  3,936)
Demographics and health status
Age, years 61.2  10.2 52.1  12.5
Female, no. (%) 40 (80.0) 3,232 (82.1)
Body mass index, kg/m2 28.2  5.2 27.6 6.3
Family history of CHD, no. (%) 9 (18.0) 519 (13.2)
History of cardiac disorders, no. (%)† 12 (24.0) 337 (8.6)
Abnormal blood pressure, no. (%)‡ 30 (60.0) 1,871 (47.5)
Current smoker, no. (%) 13 (26.0) 702 (17.8)
Concomitant medications
Oral steroids, no. (%) 31 (62.0) 2,276 (57.8)
Statins, no. (%) 8 (16.0) 348 (8.8)
NSAIDs, no. (%) 32 (64.0) 2,832 (72.0)
Methotrexate, no. (%) 35 (70.0) 3,130 (79.5)
Methotrexate dose, mg 10.9  8.1 12.0 8.2
Disease status
Duration of RA, years 9.5  6.8 9.3 8.5
Rheumatoid factor positive, no. (%) 38 (76.0) 3,050 (77.5)
DAS28 6.8  1.4 6.4 1.3
Tender joint count 17.8  9.0 14.9 7.8
Swollen joint count 14.4  6.9 11.8 6.5
Patient’s global assessment, 0–100-mm VAS 65.6 25.5 60.5 24.7
DAS28 remission, no. (%)§ 1 (2.0) 43 (1.1)
Laboratory values
Total cholesterol, mg/dl (mmoles/liter) 204.9 38.7 (5.33) 197.2 42.5 (5.07)
Total cholesterol:HDL cholesterol 4.1 1.4 3.7 1.1
HDL cholesterol, mg/dl (mmoles/liter) 54.1 15.5 (1.42) 58.0 15.5 (1.47)
LDL cholesterol, mg/dl (mmoles/liter) 123.7 38.7 (3.18) 116.0 34.8 (2.95)
Triglycerides, mg/dl (mmoles/liter) 141.7 62.0 (1.60) 124.0 70.9 (1.43)
Apolipoprotein A-I, gm/liter 1.5 0.3 1.5 0.3
Apolipoprotein B, gm/liter 1.2 0.3 1.1 0.3
Apolipoprotein B: apolipoprotein A-I 0.8 0.2 0.7 0.3
Lp(a), mg/dl 31.0  31.3 33.8 33.5
C3, gm/liter 1.4  0.3 1.4 0.3
C4, gm/liter 0.3  0.1 0.3 0.1
C-reactive protein, mg/dl 2.3  2.6 2.4 2.9
Erythrocyte sedimentation rate, mm/hour 52.0  27.1 46.1  26.8
Interleukin-6, pg/ml 37.5 44.8 42.3  61.6
Interleukin-6 receptor, ng/ml 52.1 95.4 45.6  56.6
Serum amyloid A, g/ml 54.2 77.2 61.5  83.5
Albumin, gm/liter 37.1  3.6 38.1  3.8
Haptoglobin, gm/liter 2.3 0.8 2.1  0.9
Absolute neutrophil count, 106/liter 6.0  2.0 5.8 2.4
Platelet count, 109/liter 32.6  9.2 33.3  10.0
* Except where indicated otherwise, values are the mean  SD. RA  rheumatoid arthritis; MACE 
major adverse cardiovascular event; CHD  coronary heart disease; NSAIDs  nonsteroidal antiinflam-
matory drugs; VAS  visual analog scale; HDL  high-density lipoprotein; LDL  low-density
lipoprotein.
† Defined as including any of the following Medical Dictionary for Regulatory Activities–coded terms:
angina pectoris, arrhythmia, atrial flutter, atrial fibrillation, first-degree atrioventricular block, left bundle
branch block, cardiac failure, cardiac failure congestive, cardiac valve disease, cardiomegaly, cardiomy-
opathy, coronary artery disease, hypertensive cardiomyopathy, left ventricular hypertrophy, mitral valve
incompetence, mitral valve prolapse, myocardial infarction, palpitations, sinus bradycardia, sinus tachy-
cardia, tachycardia, tachycardia paroxysmal, tricuspid valve incompetence, and ventricular extrasystole.
‡ Defined as systolic pressure 150 mm Hg or diastolic pressure 90 mm Hg.
§ Defined as a Disease Activity Score in 28 joints (DAS28) of 2.6.
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HDL cholesterol ratio and higher apolipoprotein B
(Apo B) levels, and a higher Apo B:Apo A-I ra-
tio (Figure 2). Interestingly, IL-6 and IL-6R levels at
baseline were not predictive of future MACE (HR 1.00
and HR 1.00, respectively; 95% CI 0.99–1.01 and 95%
CI 1.00–1.01, respectively [P  0.05]). In multivariable
models, older age, a history of cardiac disorders, a
higher baseline DAS28, and a higher total cholesterol:
HDL cholesterol ratio were independently associated
with MACE during TCZ treatment (Figure 3). Comple-
menting the associations observed at baseline, Cox pro-
portional hazards models using single predictors ob-
served at week 24 and adjusting for age indicated that a
higher DAS28, a larger area under the curve (AUC) of
the DAS28, and higher TJCs and SJCs at week 24 were
statistically significant predictors of future MACE (see
Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38920/abstract).
Changes in predictors of MACE between base-
line and week 24. Greater reductions in the DAS28, SJC,
and TJC from baseline to week 24 were inversely
Figure 2. Univariate analysis of associations between baseline variables (demographic characteristics and medications) (A) and laboratory and
disease parameters (B) and the occurrence of major adverse cardiovascular events (MACE) during tocilizumab treatment. An abnormal blood
pressure (BP) was defined as systolic pressure 150 mm Hg or diastolic pressure 90 mm Hg. HR  hazard ratio; 95% CI  95% con-
fidence interval; NSAIDs  nonsteroidal antiinflammatory drugs; CHD  coronary heart disease; HDL-c  high-density lipoprotein cholesterol;
Apo B apolipoprotein B; LDL-c low-density lipoprotein cholesterol; ESR erythrocyte sedimentation rate; SAA serum amyloid A; IL-6R
interleukin-6 receptor; CRP C-reactive protein; DAS28Disease Activity Score in 28 joints.  For each variable listed, a Cox regression model
was fit, with the listed variables at baseline (A and B) and age (A) as predictors. For example, for patients of the same age, each additional swollen
joint (of 28 evaluated) is associated with 6% higher risk of MACE.
376 RAO ET AL
associated with MACE, after adjusting for baseline
variable levels (Figure 4). In contrast, a reduction in the
ESR, changes in IL-6R levels, and changes in lipid levels
between baseline and 24 weeks were not statistically
significantly associated with future MACE in patients
treated with TCZ (Figure 4). Mean  SD increases in
lipid levels from baseline to week 24 were of a similar
magnitude in patients with MACE and those without
MACE: for LDL, 0.57  0.857 and 0.48  0.770
mmoles/liter, respectively; for HDL, 0.06  0.290 and
0.10  0.303 mmoles/liter, respectively; for triglycerides,
0.39 0.557 and 0.27 0.809 mmoles/liter, respectively;
for total cholesterol, 0.78  0.970 and 0.68  0.919
mmoles/liter, respectively.
DISCUSSION
To our knowledge, this study is the first to
evaluate the relationship between RA disease activity,
inflammation, and lipid parameters and the risk of CV
events in patients with RA treated with the anti–IL-6
monoclonal antibody TCZ. Because IL-6 is a key driver
of inflammation in RA, and because the rates of CVD
are higher in patients with RA compared with individu-
als without RA, we used this population to explore the
complex relationships between traditional (lipid) and
RA-specific parameters and CV risk.
In the current post hoc analyses of data for
patients with moderate to severe RA receiving TCZ, in
which 50 independently adjudicated MACE cases were
identified, we observed that a history of cardiac disor-
ders, age at baseline, the baseline atherogenic index
(ratio of total cholesterol to HDL cholesterol), and
baseline RA disease activity (as assessed using the
DAS28) were independently associated with MACE.
This is consistent with current European League Against
Rheumatism (EULAR) guidelines suggesting that the
Figure 3. Multivariable analysis of the associations between baseline factors and the occurrence of MACE during tocilizumab treatment.  
Multivariable Cox regression model. The set of predictors shown was determined through stepwise variable selection, with best score, forward
selection, and backward selection to verify robustness. See Figure 2 for definitions.
Figure 4. Age-adjusted and baseline parameter–adjusted association of changes from baseline to week 24 in lipid levels, inflammation parameters,
and RA disease activity measures with future MACE.   For each variable listed, a Cox regression model was fit, with change in the variable at
week 24, the variable at baseline, and age at baseline as predictors. The HR corresponds to increased risk of MACE per 1-unit increase in the
parameter. For example, for patients who were the same age, started treatment with the same number of swollen joints at baseline, and were treated
for 24 weeks, each additional swollen joint (of 28 evaluated) is associated with an 8% higher estimated risk of future MACE. See Figure 2 for
definitions.
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atherogenic index is the most stable marker of lipid-
associated CV risk in RA (29).
Greater reductions in RA disease activity during
TCZ therapy were associated with a statistically signifi-
cantly lower risk of MACE, whereas less-robust thera-
peutic responses (as assessed by increases in the DAS28,
SJC, and TJC from baseline to week 24) were associated
with a higher risk (HR 1). As at baseline, after 24
weeks of treatment, a future risk of MACE was broadly
linked to higher levels of disease activity as assessed
using the DAS28, the AUC of the DAS28 (a reflection
of disease burden over time), TJCs and SJCs, and a less
robust therapeutic response. Inverse associations be-
tween change in disease activity measures and MACE
are consistent with findings from an earlier study of a
registry of patients with RA treated with anti-TNF
therapy whose risk of MI was lower by more than half if
their disease responded to therapy (i.e., achievement of
a good or moderate response according to the EULAR
criteria) compared with nonresponders (11). Several
observational studies showed that use of nonbiologic
DMARDs was associated with a lower risk of MI events
in patients with RA (10,11,30). A direct association
regarding the long-term effect of TCZ treatment on
CVD cannot be determined, given that the time during
placebo treatment was limited in these trials; therefore,
no robust comparison of MACE risk in placebo-treated
patients is possible.
In the present analysis, baseline and week 24
levels of systemic markers of inflammation (ESR and
C-reactive protein [CRP]), changes in the IL-6R level
and the ESR, and changes in lipid levels over 24 weeks
of TCZ treatment were not statistically significantly
associated with future development of MACE. The lack
of association between the ESR and the CRP level and
future development of MACE may be explained by the
fact that TCZ is a potent modifier of acute-phase
reactants and, therefore, is a poor differentiator between
patients with and those without MACE with regard to
TCZ treatment (20,31). Changes in circulating levels of
IL-6 were not evaluated, because TCZ treatment blocks
IL-6R, resulting in elevated IL-6 levels in most treated
patients.
In the trials analyzed, increases in lipid para-
meters were observed soon after the initiation of TCZ;
mean total cholesterol, LDL cholesterol, HDL choles-
terol, and triglyceride levels rose by 16%, 19%, 7%, and
26%, respectively, from baseline to week 6 and remained
stable thereafter. Of note, rates of CV events did not
appear to increase over the duration of these trials and
their long-term extensions, and the CV event rates seen
were consistent with those reported in the general
population of patients with RA (32).
One possible explanation for the lack of an
observed association between increased risk of CV
events and elevated lipid levels in RA patients treated
with TCZ is that inflammation, including that mediated
by IL-6, can often lead to reduced lipid levels by
mechanisms that are not yet fully understood. Such
mechanisms may include increased peripheral catabo-
lism (e.g., via decreases in catalytically inactive lipopro-
tein lipase) (33) and up-regulation of scavenger recep-
tors leading to increased partitioning to tissue (34–36).
As such, the lipid level increases observed in association
with TCZ treatment may in part represent a predictable
response to the suppression of inflammation. Further
evidence indicating the complexity of the relationship
between lipid levels and CV risk in patients with inflam-
matory diseases is illustrated by a cohort study in which
patients with RA who had very low total cholesterol and
LDL cholesterol levels were at increased risk of CVD
(7). Longer-term prospective studies are needed to
confirm this paradoxical observation. With regard to
lipid-lowering agents, particularly statins, a low level of
use was observed in this population. The association
between statin use at baseline and increased risk of
MACE in the univariate analysis was likely due to
confounding by indication rather than to statin use itself.
Indeed, some data suggest that statins may decrease the
incidence of CV events in patients with RA (37), and a
recent report underscores the notion that statins are
likely grossly underused in the RA population (38).
The current study has several limitations. First,
this post hoc exploratory analysis of safety events was
conducted to investigate possible associations with pa-
tient characteristics, baseline laboratory values and dis-
ease activity parameters, and clinical response charac-
teristics. The results were not adjusted for multiplicity
testing, and the study was not specifically powered to
evaluate the risk of MACE; thus, these analyses
should be interpreted as hypothesis-generating. The
number of MACE events (n  50) was modest in the
population analyzed (3.4/1,000 patient-years); how-
ever, this event rate is broadly similar to that observed in
the British Biologics Registry (5.3/1,000 patient-years).
We included all potential MACE cases based on serious
adverse event reporting and then verified MACE using
blinded adjudication by an independent cardiologist.
Therefore, it is unlikely that MACE cases were missed.
In terms of statistical power to evaluate the
association between a continuous predictor and the risk
of future development of MACE, use of at least 5–10
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events per predictive variable in the model is recom-
mended to avoid bias in the estimation of regression
coefficients (39,40). Nonetheless, a Type II error (i.e.,
failure to detect an association when it is present but
potentially small) is possible. Thus, there were sufficient
events for this exploratory endeavor using primarily
simple models to evaluate potential risk factors, but they
should be interpreted cautiously. Second, treatment was
discontinued in 31% of patients during the studies.
MACE cases that occurred up to 6 months after the
discontinuation of TCZ were included in the analyses;
beyond that point, the incidence of MACE is unclear. As
such, the analyses might have been affected by informa-
tive censoring (i.e., the risk of MACE among patients
who withdrew might be different from that among
patients who remained in the studies). Furthermore,
additional time-varying confounders, including hyper-
tension, use of statins, and use of antiplatelet medica-
tions and glucocorticoids, were not evaluated. Finally,
conclusions regarding the risk of MACE beyond the
period of observation in this study (mean 3.6 years)
cannot be made.
In conclusion, our data suggest that measures of
disease activity may be independently related to the risk
of CVD in patients with RA; in addition, an elevated
atherogenic index at baseline (pretreatment) may also
be independently associated with this risk. However, and
of more importance to clinical practice, the current ana-
lysis suggests that changes in measures of RA disease
activity, but not necessarily changes in lipid levels, are
associated with incident MACE in TCZ-treated patients.
ACKNOWLEDGMENTS
We thank Jenny Devenport, PhD (Genentech), for
support with the statistical analyses and Priscilla Hsue, MD
(San Francisco General Hospital), for completing adjudication
of the MACE cases. We also thank Mark English, PhD, Santo
D’Angelo, PhD, and Meryl Mandle, who provided third-party
writing assistance funded by F. Hoffmann-La Roche Ltd.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Klearman had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Rao, Pavlov, Klearman, Musselman,
Bathon, Sattar, Lee.
Acquisition of data. Rao, Musselman.
Analysis and interpretation of data. Rao, Pavlov, Klearman, Giles,
Bathon, Sattar, Lee.
ROLE OF THE STUDY SPONSOR
F. Hoffmann-La Roche Ltd. funded the study and was
responsible for the study design in collaboration with the authors. The
sponsor collected, analyzed, and interpreted the data, with the authors
contributing to data interpretation and the drafting/revising of the
manuscript. The authors attest to the accuracy and completeness of the
reported data and had final responsibility for the decision to submit
the manuscript for publication. Publication of this article was not
contingent upon approval by F. Hoffmann-La Roche Ltd.
ADDITIONAL DISCLOSURES
Authors Klearman and Musselman are employees of Genen-
tech. Author Lee was an employee of Roche during the time when the
study was conducted.
REFERENCES
1. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J,
Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid
arthritis. Ann Rheum Dis 2006;65:1608–12.
2. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic
disease, with a focus on RA and SLE. Nat Rev Rheumatol
2011;7:399–408.
3. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV,
Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer
the same risk for cardiovascular outcomes in rheumatoid arthritis
patients as in non-rheumatoid arthritis patients? Ann Rheum Dis
2008;67:64–9.
4. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W,
Symmons D, et al. Association of the HLA–DRB1 gene with
premature death, particularly from cardiovascular disease, in
patients with rheumatoid arthritis and inflammatory polyarthritis.
Arthritis Rheum 2008;58:359–69.
5. Third report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III)
final report. Circulation 2002;106:3143–421.
6. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Ga-
briel SE. Cardiovascular death in rheumatoid arthritis: a popula-
tion-based study. Arthritis Rheum 2005;52:722–32.
7. Myasoedova E, Crowson CS, Maradit Kremers H, Roger VL,
Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid
arthritis: the impact of serum lipid measures and systemic inflam-
mation on the risk of cardiovascular disease. Ann Rheum Dis
2011;70:482–7.
8. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Jacob-
sen SJ, Roger VL, et al. Raised erythrocyte sedimentation rate
signals heart failure in patients with rheumatoid arthritis. Ann
Rheum Dis 2007;66:76–80.
9. Wolfe F, Michaud K. The risk of myocardial infarction and
pharmacologic and nonpharmacologic myocardial infarction pre-
dictors in rheumatoid arthritis: a cohort and nested case–control
analysis. Arthritis Rheum 2008;58:2612–21.
10. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the
risk of acute myocardial infarction. Arthritis Rheum 2006;55:
531–6.
11. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for
Rheumatology Biologics Register Control Centre Consortium,
Silman AJ, Symmons DP, on behalf of the British Society for
Rheumatology Biologics Register. Reduction in the incidence of
myocardial infarction in patients with rheumatoid arthritis who
respond to anti–tumor necrosis factor  therapy: results from the
British Society for Rheumatology Biologics Register. Arthritis
Rheum 2007;56:2905–12.
RISK FACTORS FOR CARDIOVASCULAR EVENTS WITH TOCILIZUMAB 379
12. Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E,
Loomba R. Association between serum interleukin-6 concentra-
tions and mortality in older adults: the Rancho Bernardo Study.
PLoS One 2012;7:e34218.
13. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman
SB, et al. Long-term interleukin-6 levels and subsequent risk of
coronary heart disease: two new prospective studies and a system-
atic review. PLoS Med 2008;5:e78.
14. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for
prevention of coronary heart disease: a Mendelian randomisation
analysis. Lancet 2012;379:1214–24.
15. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P,
Gorman DN, et al. Interleukin-6 receptor pathways in coronary
heart disease: a collaborative meta-analysis of 82 studies. Lancet
2012;379:1205–13.
16. RoACTEMRA 20 mg/ml concentrate for solution for infusion
[summary of product characteristics]. Welwyn Garden City (UK):
Roche Registration Ltd; 2012.
17. Actemra (tocilizumab) injection for intravenous infusion [pre-
scribing information]. South San Francisco (CA): Genentech, Inc;
2012.
18. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C,
Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor
inhibition with tocilizumab in patients with rheumatoid arthritis
(OPTION study): a double-blind, placebo-controlled, randomised
trial. Lancet 2008;371:987–97.
19. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R,
Sanchez A, et al. IL-6 receptor inhibition with tocilizumab im-
proves treatment outcomes in patients with rheumatoid arthritis
refractory to anti-tumour necrosis factor biologicals: results from a
24-week multicentre randomised placebo-controlled trial. Ann
Rheum Dis 2008;67:1516–23.
20. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA,
Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab
reduces disease activity in rheumatoid arthritis with inadequate
response to disease-modifying antirheumatic drugs: the Tocili-
zumab in Combination With Traditional Disease-Modifying Anti-
rheumatic Drug Therapy study. Arthritis Rheum 2008;58:2968–80.
21. Kremer JM, Blanco R, Brzosko S, Burgos-Vargas R, Halland AM,
Vernon E, et al. Tocilizumab inhibits structural joint damage in
rheumatoid arthritis patients with inadequate responses to meth-
otrexate: results from the double-blind treatment phase of a
randomized placebo-controlled trial of tocilizumab safety and
prevention of structural joint damage at one year. Arthritis Rheum
2011;63:609–21.
22. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino
JJ, et al. Comparison of tocilizumab monotherapy versus metho-
trexate monotherapy in patients with moderate to severe rheuma-
toid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:
88–96.
23. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T,
Azuma J, et al. Study of active controlled tocilizumab mono-
therapy for rheumatoid arthritis patients with an inadequate
response to methotrexate (SATORI): significant reduction in
disease activity and serum vascular endothelial growth factor by
IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12–9.
24. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R,
Klearman M, et al. Tocilizumab monotherapy is superior to
adalimumab monotherapy in reducing disease activity in patients
with rheumatoid arthritis: 24-week data from the phase 4
ADACTA trial. Ann Rheum Dis 2012;71 Suppl 3:iii152.
25. Choy E, Sattar N. Interpreting lipid levels in the context of
high-grade inflammatory states with a focus on rheumatoid arthri-
tis: a challenge to conventional cardiovascular risk actions. Ann
Rheum Dis 2009;68:460–9.
26. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi
M, Gomez-Reino J, et al. Longterm safety and efficacy of tocili-
zumab in patients with rheumatoid arthritis: a cumulative analysis
of up to 4.6 years of exposure. J Rheumatol 2013;40:768–80.
27. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de
Putte LB, van Riel PL. Modified disease activity scores that
include twenty-eight–joint counts: development and validation in a
prospective longitudinal study of patients with rheumatoid arthri-
tis. Arthritis Rheum 1995;38:44–8.
28. Furnival GM, Wilson RW Jr. Regressions by leaps and bounds.
Technometrics 1974;16:499–511.
29. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P,
Kvien TK, et al. EULAR evidence-based recommendations for
cardiovascular risk management in patients with rheumatoid ar-
thritis and other forms of inflammatory arthritis. Ann Rheum Dis
2010;69:325–31.
30. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-
Petersen K, Luukkainen RK, et al. Cardiovascular disease in
patients with rheumatoid arthritis: results from the QUEST-RA
study. Arthritis Res Ther 2008;10:R30.
31. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S,
Sugimoto M, et al. Tocilizumab inhibits signal transduction medi-
ated by both mIL-6R and sIL-6R, but not by the receptors of other
members of IL-6 cytokine family. Int Immunopharmacol 2005;5:
1731–40.
32. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van
Vollenhoven RF. Integrated safety in tocilizumab clinical trials.
Arthritis Res Ther 2011;13:R14.
33. Wallberg-Jonsson S, Dahlen G, Johnson O, Olivecrona G, Ran-
tapaa-Dahlqvist S. Lipoprotein lipase in relation to inflammatory
activity in rheumatoid arthritis. J Intern Med 1996;240:373–80.
34. Gierens H, Nauck M, Roth M, Schinker R, Schurmann C,
Scharnagl H, et al. Interleukin-6 stimulates LDL receptor gene
expression via activation of sterol-responsive and Sp1 binding
elements. Arterioscler Thromb Vasc Biol 2000;20:1777–83.
35. Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M.
Overproduced interleukin 6 decreases blood lipid levels via up-
regulation of very-low-density lipoprotein receptor. Ann Rheum
Dis 2010;69:741–6.
36. Hashizume M, Mihara M. Atherogenic effects of TNF- and IL-6
via up-regulation of scavenger receptors. Cytokine 2012;58:
424–30.
37. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr,
Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men
and women with elevated C-reactive protein. N Engl J Med
2008;359:2195–207.
38. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith
JP, et al. Statin use in rheumatoid arthritis in relation to actual
cardiovascular risk: evidence for substantial undertreatment of
lipid-associated cardiovascular risk? Ann Rheum Dis 2010;69:
683–8.
39. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per
variable in logistic and Cox regression. Am J Epidemiol 2007;165:
710–8.
40. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of
events per independent variable in proportional hazards regres-
sion analysis. II. Accuracy and precision of regression estimates.
J Clin Epidemiol 1995;48:1503–10.
380 RAO ET AL
